Related Experiment Video
Updated: Jan 16, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Epigenetic alterations in triple-negative breast cancer and their clinical implications for diagnosis and therapy
1Department of Biological Sciences, Keimyung University College of Natural Sciences, Daegu 42601, Republic of Korea.
Abstract:
Breast cancer, including triple-negative breast cancer (TNBC), is the most commonly diagnosed cancer in women, with subtypes differing in treatment options and prognoses. In particular, TNBC, characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, is the most aggressive subtype, with limited treatment options, high metastatic rates, and poor survival outcomes. In recent years, epigenetic studies have emerged as a promising tool for analyzing gene expression and alterations in TNBC, providing potential insights into the development of novel therapeutic strategies. Epigenetic mechanisms, such as DNA methylation, histone modifications, and non-coding RNA (ncRNA)-mediated gene silencing, play a crucial role in the development and progression of TNBC. Research into these mechanisms holds significant promise for the development of personalized therapeutic approaches, potentially improving outcomes for TNBC patients. This review provides a comprehensive overview of recent advances in research on epigenetic alterations in TNBC, with an emphasis on potential clinical applications aimed at improving survival and quality of life in TNBC patients.
Insights
Triple-negative breast cancer (TNBC) is aggressive with limited treatments. Epigenetic alterations in TNBC offer promising targets for developing new therapies to improve patient survival and quality of life.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Breast cancer is a leading cause of cancer death in women, with triple-negative breast cancer (TNBC) being the most aggressive subtype.
- TNBC lacks estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, leading to limited treatment options and poor prognoses.
- Epigenetic dysregulation is increasingly recognized as a key driver in TNBC development and progression.
Purpose of the Study:
- To provide a comprehensive review of recent advances in epigenetic alterations specific to TNBC.
- To highlight the role of epigenetic mechanisms in TNBC pathogenesis.
- To explore the potential clinical applications of targeting epigenetic modifications for improved TNBC treatment.
Main Methods:
- Literature review of recent studies on TNBC epigenetics.
- Analysis of epigenetic mechanisms including DNA methylation, histone modifications, and non-coding RNA.
- Focus on research linking epigenetic alterations to TNBC clinical characteristics and therapeutic strategies.
Main Results:
- Epigenetic mechanisms like DNA methylation, histone modifications, and ncRNA silencing are crucial in TNBC.
- These epigenetic alterations are associated with TNBC's aggressive behavior and metastatic potential.
- Targeting epigenetic pathways presents a promising avenue for novel therapeutic interventions in TNBC.
Conclusions:
- Epigenetic research offers significant insights into TNBC biology and progression.
- Understanding TNBC epigenetic alterations is key to developing personalized therapeutic strategies.
- Targeting epigenetics holds promise for improving survival and quality of life for TNBC patients.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:37Epigenetic Regulation
X-chromosome...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...